Showing 25 to 36 of 40 results
Weight Loss Injections: Pharmacy Access Planned
A potential multimillion-pound deal could allow pharmacies in England to offer weight loss injections like Ozempic and Wegovy for £9.90 after a short consultation, addressing current NHS limitations and long wait times.
Weight Loss Injections: Pharmacy Access Planned
A potential multimillion-pound deal could allow pharmacies in England to offer weight loss injections like Ozempic and Wegovy for £9.90 after a short consultation, addressing current NHS limitations and long wait times.
Progress
44% Bias Score
80+ UK Deaths Linked to Weight-Loss Jabs
Over 80 Britons have died, and nearly 400 required hospitalization, after using weight-loss and diabetes jabs like Ozempic and Mounjaro, prompting calls for stricter regulations and raising concerns over the drugs' accessibility.
80+ UK Deaths Linked to Weight-Loss Jabs
Over 80 Britons have died, and nearly 400 required hospitalization, after using weight-loss and diabetes jabs like Ozempic and Mounjaro, prompting calls for stricter regulations and raising concerns over the drugs' accessibility.
Progress
64% Bias Score
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Progress
48% Bias Score
GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities
A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...
GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities
A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...
Progress
40% Bias Score
GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
GLP-1 Weight-Loss Drugs: Significant Health Benefits and Risks Revealed
A study of over 2.4 million people found that GLP-1 weight-loss medications reduced the risk of 42 health conditions, including cardiac arrest and Alzheimer's disease, by reducing inflammation and improving impulse control, but increased risks of gastrointestinal issues were also observed.
Progress
36% Bias Score
Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Weight-Loss Drugs Double Pancreatitis Risk: Major Study
A Washington University study of over 2 million diabetes patients found that weight-loss drugs like Ozempic doubled the risk of pancreatitis and increased risks of nausea/vomiting (30%), arthritis (11%), headaches (10%), and sleep disturbances (12%), despite also showing benefits in cardiovascular a...
Progress
52% Bias Score
Weight-Loss Injections Linked to Increased Gallbladder Surgery Risk
Pharmacist Deborah Grayson warns of a rise in gallbladder surgeries among patients using weight-loss injections like Mounjaro, attributing the increased risk of gallstones to the drug's mechanism of slowing bile flow; this affects up to 10 percent of users, necessitating greater patient awareness an...
Weight-Loss Injections Linked to Increased Gallbladder Surgery Risk
Pharmacist Deborah Grayson warns of a rise in gallbladder surgeries among patients using weight-loss injections like Mounjaro, attributing the increased risk of gallstones to the drug's mechanism of slowing bile flow; this affects up to 10 percent of users, necessitating greater patient awareness an...
Progress
52% Bias Score
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
Progress
40% Bias Score
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Progress
36% Bias Score
Soaring Demand for Expensive Weight-Loss Drugs in the Netherlands
The number of Dutch citizens purchasing costly new weight-loss drugs increased dramatically from 2000 prescriptions in 2022 to 109,000 in 2023, raising concerns about accessibility and the strain on the healthcare system due to high costs and potential exacerbation of health inequalities.
Soaring Demand for Expensive Weight-Loss Drugs in the Netherlands
The number of Dutch citizens purchasing costly new weight-loss drugs increased dramatically from 2000 prescriptions in 2022 to 109,000 in 2023, raising concerns about accessibility and the strain on the healthcare system due to high costs and potential exacerbation of health inequalities.
Progress
52% Bias Score
GLP-1RA Medications: Reduced Risk of 42 Conditions, Increased Risk of 19 in Diabetic Patients
A study of 215,970 diabetic patients found GLP-1RA medications reduced the risk of 42 conditions (including psychotic disorders and dementia) by 13-19%, but increased the risk of 19 others (such as arthritis), based on a 3.5-year analysis of US Department of Veterans Affairs data.
GLP-1RA Medications: Reduced Risk of 42 Conditions, Increased Risk of 19 in Diabetic Patients
A study of 215,970 diabetic patients found GLP-1RA medications reduced the risk of 42 conditions (including psychotic disorders and dementia) by 13-19%, but increased the risk of 19 others (such as arthritis), based on a 3.5-year analysis of US Department of Veterans Affairs data.
Progress
40% Bias Score
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Progress
40% Bias Score
Showing 25 to 36 of 40 results